Scholar Rock Holding Corp. (NASDAQ:SRRK) saw a 24.41 percent increase in its stock price on Friday, closing at $37.41 per share due to positive investor sentiment surrounding progress on its drug candidate for spinal muscular atrophy (SMA). The company recently completed a productive meeting with the FDA regarding its biologics license application for apitegromab. Catalent Indiana, LLC, a unit of Novo Nordisk, provided an update at the meeting, affirming that the facility is on track for reinspection by the end of this year. Scholar Rock anticipates BLA resubmission and US launch next year, with plans to seek European Medicines Agency approval by mid-2026. The company also reported a widened net loss in the third quarter of the year, attributing it to higher operating costs.

Read more at Yahoo Finance: Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress